Menopur And Rekovelle Combination Study Version 2.0

Recruiting Phase 2 Interventional Study
IVF Controlled Ovarian Simulation Fertility Disorders
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 40
Sex
Female
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
200 (estimated)
Sponsor
Clinique Ovo · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is: \- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Women aged 18 to 40 years inclusively at the time of consent form signature * Diagnosis of unexplained infertility, tubal infertility, endometriosis stage I/II or male factor infertility * Regular menstrual cycles of 24-35 days * Presence of both ovaries * Early follicular pha…
Contacts

Marya Far

514-798-2000

m.far@cliniqueovo.com

CONTACT